Shandong Buchang Pharmaceuticals (603858.SH) plans to sign a termination agreement with Nantong Lianya for development, supply, and sales.

Shandong Buchang Pharmaceuticals (603858.SH) announced that, according to a previous announcement, on August 17, 2017, the company held the 25th (special) meeting of the second session of the Board of Directors and approved the "Proposal on the Company's Intended Cooperation with Nantong Lianya Pharmaceutical Co., Ltd. in the Development, Supply and Sale of Drugs and Related Matters. The company intends to sign a "Development, Supply and Sales Agreement" with Nantong Lianya Pharmaceutical Co., Ltd. (now known as "Nantong Lianya Pharmaceutical Co., Ltd.", referred to as "Nantong Lianya") for 5 products including controlled-release nifedipine tablets. Taking into account the current market environment and the actual operating conditions of the company, the company has reached a friendly agreement with Nantong Lianya and decided to terminate the "Development, Supply and Sales Agreement" and the "Contract Change Agreement for Technical Development (Cooperation)" (hereinafter referred to as the "original agreement") and sign a "Development, Supply and Sales Termination Agreement".